Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.76 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.76 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 5/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | TEK | Q02763 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 4/20 | 0.67 |
| ▸ | ITK | Q08881 | 3/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | YES1 | P07947 | 1/20 | 0.60 |
| ▸ | HCK | P08631 | 1/20 | 0.60 |
| ▸ | FGR | P09769 | 1/20 | 0.60 |
| ▸ | FER | P16591 | 1/20 | 0.60 |
| ▸ | CSK | P41240 | 1/20 | 0.60 |
| ▸ | TEC | P42680 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439227 | 1.00 | BTK (0.76) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22720762 | 0.99 | BTK (0.75) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL29439192 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22720917 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL29439093 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL29439211 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22721008 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22720796 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22720894 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL29439197 | 0.96 | BTK (0.71) | BTKNUDT14NUDT5LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027041-A | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240018147-A1 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | HAISCO PHARMACEUTICALS PTE. LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018147-A1 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | HAISCO PHARMACEUTICALS PTE. LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018147-A1 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | HAISCO PHARMACEUTICALS PTE. LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-113544130-B | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4253384-A1 | METHOD FOR PREPARING BTK DEGRADING AGENT | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2023-10-04 | — | — | EP | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| CN-116568679-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-116134028-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| CN-114539264-A | Preparation method of BTK (benzene-toluene-xylene) degrading agent | 海思科医药集团股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022052950-A1 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | 海思科医药集团股份有限公司 | 2022-03-17 | — | — | WO | disclosed |
| WO-2022007824-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018147-A1 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | BTK, SYK, LYN | BTK 1/4885NUDT14 2377/4885NUDT5 2641/4885 |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | BTK 1/4885NUDT14 3824/4885NUDT5 2932/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | BTK 1/4885NUDT14 3438/4885NUDT5 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.